Immutep (ASX:IMM) has announced that the open-label safety lead-in of its integrated AIPAC-003 Phase 2/3 trial evaluating 90mg of eftilagimod alpha (efti) in combination with paclitaxel has been completed with no safety or tolerability issues. …
Immutep announces the completion of key stage of AIPAC-003 trial in metastatic breast cancer
November 6, 2023 Australian Biotech
Latest Video
New Stories
-
The industry walked out on Britain, and what it cost to win them back
October 22, 2026 - - Latest News -
BioNTech opens mRNA plant, putting Melbourne's north on the biotech map
October 22, 2026 - - Latest News -
An architect of the first industry–Commonwealth medicines pact to lead CSL
October 21, 2026 - - Latest News -
Quarterly update shows Telix holds course for a US$1 billion milestone year
October 21, 2026 - - Latest News -
Chemist Warehouse keeps growing as Sigma sets its sights on oral GLP-1s
October 21, 2026 - - Latest News -
America's ever rising GLP-1 curve and how Australia is following
October 21, 2026 - - Latest News -
Patient groups across Asia-Pacific push for a say on medicine prices
October 21, 2026 - - Latest News